Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10632066 | THERAPEUTICSMD INC | Method of providing birth control |
Feb, 2039
(16 years from now) | |
US10780047 | THERAPEUTICSMD INC | Method of providing birth control |
Feb, 2039
(16 years from now) | |
US10765628 | THERAPEUTICSMD INC | Method of providing birth control |
Feb, 2039
(16 years from now) | |
US10918649 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(16 years from now) | |
US10925882 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(16 years from now) | |
US10940157 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(16 years from now) | |
US11529308 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Aug 10, 2023 |
NCE-1 date: August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: Method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any such cycle without using alternative contraception; Method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles
Dosage: RING;VAGINAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic